Neurocrine Biosciences
NBIX
#1464
Rank
NZ$26.47 B
Marketcap
NZ$260.47
Share price
-1.19%
Change (1 day)
10.03%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): NZ$11.51

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$11.34. In 2025 the company made an earnings per share (EPS) of NZ$8.15 an increase over its 2024 EPS that were of NZ$5.71.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$11.5141.25%
2025NZ$8.1542.6%
2024NZ$5.7133.07%
2023NZ$4.2957.76%
2022NZ$2.7269.47%
2021NZ$1.61-78.21%
2020NZ$7.37990%
2019NZ$0.6881.82%
2018NZ$0.37-113.5%
2017NZ-$2.760.62%
2016NZ-$2.7457.28%
2015NZ-$1.7425.61%
2014NZ-$1.3918.84%
2013NZ-$1.17-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.21-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$3.48-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$47.72 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$1.56-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.43-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$6.95-38.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$12.76-212.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.22-71.61%๐Ÿ‡ฌ๐Ÿ‡ง UK